Prescient Therapeutics opens first US site for PTX-100 trial
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Prescient Therapeutics has crossed a major milestone in its international expansion, with the first US...
Stockhead’s Tylah Tully catches up with Prescient Therapeutics (ASX:PTX) CEO James McDonnell after the company hit a...
Prescient Therapeutics CEO James McDonnell talked with Proactive about promising developments surrounding the company’s lead...
For those affected by Cutaneous T-Cell Lymphoma (CTCL), a rare and aggressive cancer, treatment options...
Prescient Therapeutics is focused on development of lead compound PTX-100 to treat rare blood cancer
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the...
One in five people will get cancer in their lifetime – almost everyone has been...
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.